- Home
- ARCT vs AURA Comparison
ARCT vs AURA Comparison
Compare ARCT & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- AURA
- Stock Information
- Founded
- ARCT 2013
- AURA 2007
- Country
- ARCT United States
- AURA United States
- Employees
- ARCT N/A
- AURA N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- AURA Biotechnology: Pharmaceutical Preparations
- Sector
- ARCT Health Care
- AURA Health Care
- Exchange
- ARCT Nasdaq
- AURA Nasdaq
- Market Cap
- ARCT 602.7M
- AURA 572.0M
- IPO Year
- ARCT N/A
- AURA 2021
- Fundamental
- Price
- ARCT $16.02
- AURA $9.47
- Analyst Decision
- ARCT Strong Buy
- AURA Strong Buy
- Analyst Count
- ARCT 7
- AURA 4
- Target Price
- ARCT $65.00
- AURA $23.00
- AVG Volume (30 Days)
- ARCT 400.2K
- AURA 184.2K
- Earning Date
- ARCT 11-07-2024
- AURA 11-12-2024
- Dividend Yield
- ARCT N/A
- AURA N/A
- EPS Growth
- ARCT N/A
- AURA N/A
- EPS
- ARCT N/A
- AURA N/A
- Revenue
- ARCT $160,399,000.00
- AURA N/A
- Revenue This Year
- ARCT $13.02
- AURA N/A
- Revenue Next Year
- ARCT $5.58
- AURA N/A
- P/E Ratio
- ARCT N/A
- AURA N/A
- Revenue Growth
- ARCT N/A
- AURA N/A
- 52 Week Low
- ARCT $14.93
- AURA $6.63
- 52 Week High
- ARCT $45.00
- AURA $12.38
- Technical
- Relative Strength Index (RSI)
- ARCT 31.24
- AURA 39.43
- Support Level
- ARCT $18.90
- AURA $10.48
- Resistance Level
- ARCT $21.61
- AURA $11.29
- Average True Range (ATR)
- ARCT 1.15
- AURA 0.56
- MACD
- ARCT -0.07
- AURA -0.18
- Stochastic Oscillator
- ARCT 16.32
- AURA 2.67
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.